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Discussion
Dr R. Scott Mitchell (Stanford, Calif ). Dr Arnaoutakis, you and
your colleagues are to be complimented for an excellent report.
Your study embracing the relatively new RIFLE classification
introduces a very desirable standardization with three grades of
renal injury—risk, injury, and failure—in increasing severity.
These grades of severity are based exclusively on postoperative
changes in plasma creatinine, GFR, or urinary output. Its strengths
are the ability to compare apples with apples, which we desper-
ately need as we manipulate postoperative variables. This is a
much needed standardization.
Its weakness, to my eye, however, is that it really is predictive
of only things after the surgical event, which is the one time where
we may most capably modulate the renal injury. Certainly intra-
operative variables may be very important to postoperative patient
performance. I wonder whether you might have included in your
variables such things as perfusion strategies, antegrade versus
retrograde perfusion through axillary arteries or femoral cannula-
tion, or whether you looked at the effect of temperatures, since
temperature and bypass times may be correlated.
Would you agree that more intraoperative variables might be
introduced into this model so that you can be more predictive?
Second, do you think the actual protective effect that you saw for
the reoperative patients was due, as you suggested, to the de-
creased incidence of emergency operations in that patient cohort or
to some other effect?
Dr Arnaoutakis. Thank you, Dr. Mitchell, for your excellent
points and questions. I should echo the points that you made that
this system is not instated to be a predictive tool, but rather a
classification system, such that in future studies we would be
comparing apples with apples. The hope is to disseminate a wide-
spread nomenclature that we can use when discussing renal failure.
With respect to your questions regarding variables, in our early
experience most patients were cannulated by the femoral artery;
however, recently we have adopted selective use of axillary can-
nulation and we do have plans to review these data and perhaps
incorporate them into some of our models.
With respect to your second question concerning the redo, this
was a curious finding to us as well. Patients in this series were
homogeneous in that all required use of circulatory arrest; how-
ever, they were operated on primarily for one of two diseases:
aortic aneurysms or acute aortic dissections. In looking back at the
data, because of this peculiar finding, we found that nearly 90% of
the redo operations were in an elective setting for aneurysmal
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disease and most of the acute aortic dissections were first-time
operations and occasionally undertaken in the setting of profound
systemic shock.
Dr Gary H. Dworkin (Clearwater, Fla). With regard to Dr
Mitchell’s suggestion of intraoperative variables, did you appreci-
ate any changes or look at the use of aprotinin or other antifibrino-
lytics and relate them to your postoperative outcomes?
Dr Arnaoutakis. Thank you, Dr Dworkin, for your question
as well. We are eminently aware of the ongoing debate regard-
ing aprotinin. As a matter of fact, we did look at aprotinin. In
our early experience, some patients did receive epsilon amin-
ocaproic acid; however, in this series, the majority of patients,
nearly 90%, had received aprotinin. We did look at it in the
model and it did not come out to be significant for any of the
outcomes we looked at. However, we concluded that since there
was such a disparity in the number of patients who received
aprotinin versus epsilon aminocaproic acid, we had low power
to detect any significant differences.
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